Aurora Quinase
Os inibidores da quinase Aurora têm como alvo as quinasas Aurora, uma família de quinasas serina/treonina que desempenham um papel crucial na regulação da mitose. Essas quinasas são essenciais para o alinhamento adequado dos cromossomos, segregação e citocinese durante a divisão celular. A atividade anormal da quinase Aurora pode levar à proliferação celular descontrolada e ao câncer. Ao inibir as quinasas Aurora, esses compostos podem induzir a parada do ciclo celular e a apoptose em células cancerígenas, tornando-os ferramentas valiosas na pesquisa e terapia do câncer. Na CymitQuimica, oferecemos uma ampla gama de inibidores de quinasas Aurora de alta qualidade para apoiar sua pesquisa em regulação do ciclo celular, mitose e oncologia.
Foram encontrados 111 produtos de "Aurora Quinase"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
NU6140
CAS:<p>NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).</p>Fórmula:C23H30N6O2Pureza:98.33%Cor e Forma:SolidPeso molecular:422.52Tinengotinib
CAS:Tinengotinib is a multikinase inhibitor that targets a series of kinases , including Aurora kinases A/B, JAK1/2, FGFR1/2/3, VEGFRs, and many other kinases.Fórmula:C20H19ClN6OPureza:99.05%Cor e Forma:SolidPeso molecular:394.86Centrinone
CAS:Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).Fórmula:C26H25F2N7O6S2Pureza:98.76%Cor e Forma:SolidPeso molecular:633.65TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Fórmula:C28H32N4O3SPureza:99.02% - 99.59%Cor e Forma:SolidPeso molecular:504.64dAURK-4 hydrochloride
dAURK-4 hydrochloride, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].Fórmula:C52H53Cl2FN8O12Pureza:99.44%Cor e Forma:SolidPeso molecular:1071.93TAS-119
CAS:TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95Fórmula:C23H22Cl2FN5O3Pureza:99.65%Cor e Forma:SolidPeso molecular:506.36SK2187
CAS:SK2187 is a selective degrader of AURKAPROTAC with a DC50 of approximately 10 nM. It exhibits growth-inhibitory effects on NGP cells, with an IC50 value of 101.5 nM. SK2187 is utilized in studies of MYCN-amplified neuroblastoma.Fórmula:C45H49ClFN7O11SCor e Forma:SolidPeso molecular:950.43dAurAB2
dAurAB2 is a bifunctional PROTAC capable of effectively degrading Aurora-A and Aurora-B, with DC50 values of 59 nM and 39 nM, respectively. It reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells and is valuable for neuroblastoma research.Cor e Forma:Odour SolidPROTAC MPS1 degrader 1
PROTAC MPS1 degrader 1 (Compound 19) acts as a potent degrader of Monopolar spindle 1 (Mps1, TTK), AURKA, and AURKB, with DC50 values of 17.7, 108.7, and 570.3 nM respectively. It is utilized in the study of acute myeloid leukemia. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase)Fórmula:C41H46N12O7Cor e Forma:SolidPeso molecular:818.88PROTAC MPS1 degrader 2
PROTAC MPS1 Degrader 2 (Compound 15) is a potent degrader of monopolar spindle 1 (Mps1, TTK), AURKA, and AURKB with DC50 values of 42.0, 2.1, and 154.0 nM respectively. It is utilized in the research of acute myeloid leukemia.Fórmula:C41H41N11O8SCor e Forma:SolidPeso molecular:847.90AKI603
CAS:AKI603: Aurora A kinase blocker; IC50 12.3 nM; targets BCR-ABL-T315I resistance; halts leukemia cell growth.Fórmula:C19H23N9O2Pureza:99.81%Cor e Forma:SolidPeso molecular:409.45Retreversine
CAS:Retreversine serves as an inactive control counterpart to Reversine, a pioneering class of ATP-competitive Aurora kinase inhibitor.Fórmula:C21H27N7OCor e Forma:SolidPeso molecular:393.49dAURK-4
CAS:dAURK-4, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].Fórmula:C52H52ClFN8O12Cor e Forma:SolidPeso molecular:1035.47CAM2602
<p>CAM2602 is an inhibitor of Aurora A-TPX2 interaction, demonstrating a binding affinity of 19 nM with Aurora A. This compound has been shown to inhibit the growth of pancreatic cancer cells. In solid tumor xenograft models, CAM2602 increases the proportion of PH3-positive cells while decreasing the ratio of P-Thr288Aurora A-positive cells, ultimately inhibiting tumor growth.</p>Cor e Forma:Odour SolidAURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Cor e Forma:SolidPeso molecular:545.61JB170
CAS:JB170 is a specific Aurora A degradator. Alisertib and Thalidomide, induces S-phase arrest in cell growth and inhibits the non-catalytic function.Fórmula:C48H44ClFN8O11Pureza:99.82%Cor e Forma:SolidPeso molecular:963.3611α-O-Tigloyl-12β-O-acetyltenacigenin B
CAS:11α-O-Tigloyl-12β-O-acetyltenacigenin B, an ester derivative isolated from Garcinia cambogia (MTC), modulates the antitumor effects of Aurora-A in lymphomaFórmula:C28H40O7Pureza:98%Cor e Forma:SolidPeso molecular:488.61Aurora kinase-IN-7
Aurora kinase-IN-7 (compound 4b) is an orally active inhibitor selectively targeting AURKB. It is utilized in the study of aggressive cancers.Fórmula:C26H21FN6OPeso molecular:452.48JB300
CAS:JB300 is a PROTAC-based compound that serves as a highly selective degrader of Aurora A, with a DC50 of 30 nM. It is utilized in cancer research. JB300 comprises the PROTAC target protein ligand MK-5108 [pink part], E3 ligase ligand Thalidomide-O-COOH [blue part], and PROTAC Linker Boc-NH-PEG2-C2-NH2 [black part]. The conjugate of the E3 ubiquitin ligase ligand and linker is Thalidomide-O-COOH-NH2-C2-PEG2-NH-Boc.Fórmula:C43H45ClFN7O10SCor e Forma:SolidPeso molecular:906.375Barasertib
CAS:AZD1152 is a pro-drug of Barasertib (AZD1152)-hQPA. Which is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay.Fórmula:C26H31FN7O6PPureza:99.92% - 99.97%Cor e Forma:SolidPeso molecular:587.54CD532 hydrochloride
CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.Cor e Forma:SolidSP-96
CAS:<p>SP-96: Aurora B inhibitor, IC50=0.316 nM, selectively hinders MDA-MD-468 growth, GI50=107 nM, for triple-negative breast cancer research.</p>Fórmula:C25H20FN7OPureza:99.54%Cor e Forma:SolidPeso molecular:453.47GSK-1070916
CAS:GSK-1070916 (GSK-1070916A) is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM.Fórmula:C30H33N7OPureza:99.73%Cor e Forma:SolidPeso molecular:507.63HLB-0532259
CAS:<p>HLB-0532259 is a PROTAC degrader that targets the degradation of Aurora-A and N-Myc. In non-MYCN amplified MCF-7 cells, it degrades Aurora-A with a DC50 of 20.2 nM, and in MYCN amplified SK-N-BE and Kelly cells, it degrades N-Myc with DC50 values of 179 nM and 229 nM, respectively. HLB-0532259 has demonstrated antitumor activity in mouse models. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligaseCereblon)</p>Fórmula:C40H44N8O7Cor e Forma:SolidPeso molecular:748.827Aurora-A ligand 1
CAS:Aurora-A ligand 1 is a potent and selective inhibitor of Aurora-A, exhibiting a dissociation constant (Kd) of 0.85 nM. It serves as a target protein ligand [PROTAC target protein ligand] in the development of PROTAC Aurora-A degraders with antitumor activity. Additionally, Aurora-A ligand 1 is utilized in the synthesis of HLB-0532259, which exhibits antitumor effects against neuroblastoma.Fórmula:C21H23N5O3Cor e Forma:SolidPeso molecular:393.439Aurora A inhibitor 3
<p>Aurora A Inhibitor 3 (Compound 5h) effectively inhibits Aurora-A kinase, exhibiting an IC50 of 0.78 μM, and demonstrates cytotoxicity against MCF-7 and MDA-MB-</p>Pureza:98%Cor e Forma:Odour SolidMS44
MS44 is a potent degrader of aurora kinase B (AURKBPROTAC) with a degradation concentration (DC50) of 103 nM. It effectively and selectively degrades AURKB in a time- and ubiquitin-proteasome system (UPS)-dependent manner, showing specificity for AURKB over AURKA and AURKC. MS44 inhibits the proliferation of various cancer cell lines and strongly induces G2/M arrest. It is useful for studying AURKB-dependent tumors.Cor e Forma:Odour SolidMLN8054 sodium
CAS:MLN8054 sodium is an Aurora A inhibitor.Fórmula:C25H14ClF2N4NaO2Cor e Forma:SolidPeso molecular:498.84PF 477736
CAS:PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (Fórmula:C22H25N7O2Pureza:97.58% - 99.94%Cor e Forma:SolidPeso molecular:419.48Phthalazinone pyrazole
CAS:Phthalazinone pyrazole: a potent, selective oral Aurora-A kinase inhibitor, overexpressed in tumors with oncogenic activity.Fórmula:C18H15N5OPureza:97.03%Cor e Forma:SolidPeso molecular:317.34TCS7010
CAS:TCS7010 (Aurora A Inhibitor I) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay.Fórmula:C31H31ClFN7O2Pureza:98.49% - 99.62%Cor e Forma:SolidPeso molecular:588.07Ilorasertib
CAS:Ilorasertib (ABT-348) inhibits Aurora kinases A/B/C & RET, PDGFRβ, Flt1 (IC50: 1-120 nM).Fórmula:C25H21FN6O2SPureza:96.17% - 97.49%Cor e Forma:SolidPeso molecular:488.54Hesperadin
CAS:Hesperadin(IC50=250 nM) effectively inhibits Aurora B.Fórmula:C29H32N4O3SPureza:98.04% - 99.44%Cor e Forma:SolidPeso molecular:516.65CYC-116
CAS:CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not activeFórmula:C18H20N6OSPureza:97.36% - 97.59%Cor e Forma:SolidPeso molecular:368.46SP-146
<p>SP-146 is a selective, potent and non-ATP-competitive Aurora B inhibitor(IC50 : 0.316 nM).</p>Fórmula:C25H20FN7OPureza:97.82%Cor e Forma:SolidPeso molecular:453.47MK-8745
CAS:<p>MK-8745 is a potent and selective Aurora A inhibitor.</p>Fórmula:C20H19ClFN5OSPureza:99.09% - 99.79%Cor e Forma:SolidPeso molecular:431.91CCT 137690
CAS:CCT 137690 is a highly specific and oral-available aurora kinase inhibitor, for aurora A(IC50=15 nM ), B(IC50=25 nM) and C(IC50=19 nM).Fórmula:C26H31BrN8OPureza:98.51% - 99.89%Cor e Forma:SolidPeso molecular:551.48SNS-314 Mesylate
CAS:SNS-314 Mesylate (SNS-314) is an effective and specific Aurora A/B/C inhibitor. SNS-314 is less inhibition of Trk A/B, Fms, Flt4, c-Raf, Axl, and DDR2.Fórmula:C18H15ClN6OS2·CH4O3SPureza:99.44% - 99.92%Cor e Forma:SolidPeso molecular:527.047BIO
CAS:<p>7BIO triggers nonapoptotic death, blocks FLT3, DYRK1A/2, Aurora B/C kinases.</p>Fórmula:C16H10BrN3O2Pureza:99.67%Cor e Forma:SolidPeso molecular:356.17AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Cor e Forma:SolidPeso molecular:381.43SNS-314
CAS:<p>SNS-314 inhibits Aurora kinases A and B, blocking cell division in AK-overexpressing tumors.</p>Fórmula:C18H15ClN6OS2Pureza:98%Cor e Forma:SolidPeso molecular:430.93Reversine
CAS:Reversine, a small synthetic purine analogue (2, 6-disubstituted purine), is a potent inhibitior of Aurora A/B/C(IC50s=150-500 nM).Fórmula:C21H27N7OPureza:98% - 99.45%Cor e Forma:SolidPeso molecular:393.49BI-847325
CAS:BI-847325 is a selective dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively.Fórmula:C29H28N4O2Pureza:97.13% - 97.54%Cor e Forma:SolidPeso molecular:464.56Aurora kinase inhibitor-2
CAS:Aurora kinase inhibitor-2 (IUN-70219) is a cell-permeable anilinoquinazoline that inhibit the activity of Aurora A (IC50 = 0.39 M).Fórmula:C23H20N4O3Pureza:98.66%Cor e Forma:SolidPeso molecular:400.43Protein kinase inhibitor 6
CAS:<p>Protein kinase inhibitor 6 is a protein kinase inhibitor.</p>Fórmula:C13H9FN2SPureza:98.01%Cor e Forma:SolidPeso molecular:244.29Alisertib
CAS:Alisertib (MLN 8237) is a specific Aurora A inhibitor (IC50: 1.2 nM). The selectivity of Alisertib(MLN 8237) is >200-fold higher for Aurora A than Aurora B.Fórmula:C27H20ClFN4O4Pureza:98.31% - >99.99%Cor e Forma:SolidPeso molecular:518.92MLN8054
CAS:MLN8054 is a potent and selective Aurora A kinase inhibitor with an IC50 of 4 nM.Fórmula:C25H15ClF2N4O2Pureza:98.07% - 98.26%Cor e Forma:SolidPeso molecular:476.86ZM-447439
CAS:ZM 447439 selectively inhibits Aurora A/B (IC50: 110/130 nM); 8x less effective on MEK1, Src, Lck; minimal impact on CDK1/2/4, Plk1, Chk1.Fórmula:C29H31N5O4Pureza:99.11% - 99.59%Cor e Forma:Pale Yellow SolidPeso molecular:513.59AT-9283 HCl
CAS:AT-9283, a multi-targeted kinase inhibitor, is used potentially for the treatment of multiple myeloma.Fórmula:C19H24ClN7O2Cor e Forma:SolidPeso molecular:417.89TAK-632
CAS:TAK-632 is a potent pan-Raf inhibitor.Fórmula:C27H18F4N4O3SPureza:98% - 99.5%Cor e Forma:SolidPeso molecular:554.52VX-11e
CAS:VX-11e (TCS ERK 11e) is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.Fórmula:C24H20Cl2FN5O2Pureza:98.92% - ≥98%Cor e Forma:SolidPeso molecular:500.35Aurora kinase inhibitor-3
CAS:Aurora kinase inhibitor-3 (Aurora Kinase Inhibitor III) is a potent inhibitor of Aurora A kinase (IC50 = 42 nM).1 It is selective for Aurora A over BMX, BTK,Fórmula:C21H18F3N5OPureza:98.91%Cor e Forma:SolidPeso molecular:413.4URMC-099
CAS:URMC-099: oral, brain-accessible MLK/LRRK2 inhibitor; IC50 – MLK1/2/3/DLK: 19/42/14/150 nM, LRRK2: 11 nM.Fórmula:C27H27N5Pureza:99.32% - 99.98%Cor e Forma:SolidPeso molecular:421.54Danusertib
CAS:<p>Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity.</p>Fórmula:C26H30N6O3Pureza:97.88% - 98.79%Cor e Forma:White PowderPeso molecular:474.55KW-2449
CAS:KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.Fórmula:C20H20N4OPureza:98.43% - 99.69%Cor e Forma:SolidPeso molecular:332.4JNJ-7706621
CAS:<p>JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2.</p>Fórmula:C15H12F2N6O3SPureza:99.1% - 99.85%Cor e Forma:SolidPeso molecular:394.36Palmatine chloride
CAS:Palmatine chloride an isoquinoline alkaloid, is an important medicinal herbal extract with diverse pharmacological and biological properties.Fórmula:C21H22ClNO4Pureza:97.9% - 99.47%Cor e Forma:SolidPeso molecular:387.86Palmatine
CAS:<p>Palmatine, also known as Burasaine, inhibits dopamine production and may treat flavivirus, jaundice, dysentery, hypertension, and liver issues.</p>Fórmula:C21H22NO4Pureza:96.28% - 99.49%Cor e Forma:SolidPeso molecular:352.4XL228
CAS:XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).Fórmula:C22H31N9OPureza:99.07%Cor e Forma:SolidPeso molecular:437.54Tozasertib
CAS:Tozasertib (MK-0457) is a pan-Aurora kinase inhibitor (Kis: 0.6/18/4.6 nM for Aurora A/Aurora B/Aurora C).Fórmula:C23H28N8OSPureza:99.99%Cor e Forma:SolidPeso molecular:464.59PHA-680632
CAS:<p>PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively.</p>Fórmula:C28H35N7O2Pureza:98.2%Cor e Forma:SolidPeso molecular:501.62GW779439X
CAS:GW779439X is an inhibitor of CDK.Fórmula:C22H21F3N8Pureza:97.87%Cor e Forma:SolidPeso molecular:454.45AMG 900
CAS:<p>AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM.</p>Fórmula:C28H21N7OSPureza:98.4% - 99.51%Cor e Forma:SolidPeso molecular:503.58CCT241736
CAS:CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3Fórmula:C22H23Cl2N7Pureza:96.2% - 99.81%Cor e Forma:SolidPeso molecular:456.37ENMD-2076
CAS:ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.Fórmula:C21H25N7Pureza:97.63% - ≥95%Cor e Forma:SolidPeso molecular:375.47Barasertib-HQPA
CAS:<p>Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor (IC50: 0.37 nM) and demonstrates ~3,700-fold greater selectivity than Aurora A.</p>Fórmula:C26H30FN7O3Pureza:98.43% - 99.29%Cor e Forma:SolidPeso molecular:507.56MK-5108
CAS:MK-5108 (VX-689) is a highly potent and specific Aurora-A kinase inhibitor with an IC50 value of 0.064 nM.Fórmula:C22H21ClFN3O3SPureza:99.22%Cor e Forma:SolidPeso molecular:461.94SCH-1473759 hydrochloride
CAS:SCH-1473759 hydrochloride is an inhibitor of aurora(aurora A and B with IC50s of 4 and 13 nM, respectively).Fórmula:C20H27ClN8OSPureza:98.29%Cor e Forma:SolidPeso molecular:463TAK-285
CAS:TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.Fórmula:C26H25ClF3N5O3Pureza:99.73%Cor e Forma:SolidPeso molecular:547.96GW843682X
CAS:GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).Fórmula:C22H18F3N3O4SPureza:99.92%Cor e Forma:SolidPeso molecular:477.46Aurora kinase inhibitor-10
CAS:Aurora kinase inhibitor-10 is an orally active Aurora B inhibitor (IC50: 8 nM) that exhibits antitumour effects.Fórmula:C21H19F5N6O4SCor e Forma:SolidPeso molecular:546.47BI-831266
CAS:BI-831266 is a potent and selective Aurora kinase B inhibitor.Fórmula:C27H38ClN7O2Cor e Forma:SolidPeso molecular:528.09RET-IN-19
CAS:<p>RET-IN-19, a potent RET inhibitor, anticancer: IC50 6.8 nM (RET-wt), 13.51 nM (RET V804M); for NSCLC research.</p>Fórmula:C28H28N6O4SCor e Forma:SolidPeso molecular:544.62Aurora Kinases-IN-2
CAS:Aurora Kinases-IN-2 (12Aj) hinders Aurora A/B kinases (IC50: 90/152 nM), used in cancer studies.Fórmula:C22H18ClN5O3Cor e Forma:SolidPeso molecular:435.86L 888607 Racemate
CAS:L 888607 Racemate blocks DP1 and TP receptors with 132 nM and 17 nM affinity.Fórmula:C19H15ClFNO2SCor e Forma:SolidPeso molecular:375.84Ilorasertib hydrochloride
CAS:Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s:Fórmula:C25H22ClFN6O2SPureza:98.45%Cor e Forma:SolidPeso molecular:525SAR156497
CAS:SAR156497: selective Aurora A/B/C inhibitor; IC50: 0.5 nM (A), 1 nM (B), 3 nM (C); good metabolic stability; anti-tumoral without genetic specificity.Fórmula:C27H24N4O4Cor e Forma:SolidPeso molecular:468.5HOI-07
CAS:HOI-07 is a specific Aurora B inhibitor.Fórmula:C19H13NO4Cor e Forma:SolidPeso molecular:319.31OM-137
CAS:OM137 inhibits Aurora kinases, impedes cell growth at high doses, and enhances low-dose paclitaxel effects.Fórmula:C13H14N4O3SCor e Forma:SolidPeso molecular:306.34Aurora Kinases-IN-3
CAS:Aurora Kinases-IN-3 is an oral AURKB inhibitor that disrupts its mitotic localization, not its H3 Ser10 phosphorylation.Fórmula:C20H16F3N3O4Cor e Forma:SolidPeso molecular:419.35VE-465
CAS:VE-465 is an inhibitor of Aurora kinase, which involves in multiple mitotic events.Fórmula:C22H28N8OSCor e Forma:SolidPeso molecular:452.58FAK/aurora kinase-IN-1
CAS:FAK/aurora kinase-IN-1, a dual inhibitor of FAK and aurora kinase, has IC50 values of 6.61 nM and 0.91 nM respectively, and demonstrates anticancer effects (WO2018019252A1; compound 11) [1].Fórmula:C23H24ClN7O3Cor e Forma:SolidPeso molecular:481.93Aurora A/PKC-IN-1
CAS:Aurora A/PKC-IN-1 inhibits AurA (IC50: 6.9 nM), PKCα (IC50: 16.9 nM), and hinders breast cancer cell growth and spread.Fórmula:C16H14N6OSe2Cor e Forma:SolidPeso molecular:464.24Binucleine 2
CAS:Binucleine 2: Drosophila Aurora B kinase inhibitor (Ki=0.36μM), dose-dependent, minimal effect on human/X. laevis kinases, disrupts mitosis in fly cells.Fórmula:C13H11ClFN5Cor e Forma:SolidPeso molecular:291.71Aurora kinase inhibitor-9
CAS:Aurora kinase inhibitor-9 (9d) targets AURKA/B with IC50: 0.093 μM for A and 0.09 μM for B, with wide anti-proliferative effects.Fórmula:C19H17Cl2N3O4SCor e Forma:SolidPeso molecular:454.33Tripolin A
CAS:<p>Tripolin A is a specific non-ATP competitive inhibitor of Aurora A kinase(Aurora A and Aurora B with IC50 values of 1.5 μM and 7 μM, respectively)</p>Fórmula:C15H11NO3Pureza:98%Cor e Forma:SolidPeso molecular:253.25Chiauranib
CAS:<p>Chiauranib, a potent anticancer agent, inhibits angiogenesis kinases (VEGFR1-3, PDGFRα, c-Kit), Aurora B, and CSF1R with IC50 values of 1-9 nM.</p>Fórmula:C27H21N3O3Pureza:99.22%Cor e Forma:SolidPeso molecular:435.47GRK6-IN-1
CAS:GRK6-IN-1 (compound 18) is a potent GRK6 blocker, with an IC50 of 120 nM, showing promise for multiple myeloma research.Fórmula:C22H23ClN6O2Pureza:99.37%Cor e Forma:SolidPeso molecular:438.91CD532
CAS:CD532: Potent Aurora A inhibitor, IC50=45 nM, blocks kinase activity, degrades MYCN, interacts with AURKA, studies cancer.Fórmula:C26H25F3N8OPureza:99.99%Cor e Forma:SolidPeso molecular:522.52GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Fórmula:C24H26N2O2Cor e Forma:SolidPeso molecular:374.48GRK2 Inhibitor 2
CAS:GRK2 Inhibitor 2 (Compound 8h), with an IC50 of 19 nM for GRK2 and 137 nM for Aurora-A, enhances β-AR-mediated cAMP accumulation in GRK2-overexpressing HEK293Fórmula:C19H16N4O2Cor e Forma:SolidPeso molecular:332.36GW814408X
CAS:GW814408X, a kinase chemical genome group (KCGS) compound, inhibits the AURKC kinase, which is involved in cell cycle progression, checkpoint regulation, and cell division. It exhibits cell line-dependent toxicity, such as cytotoxic effects on HeLa cells, and acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases, potentially impacting Fluc reporter assays [1].Fórmula:C19H16N6OPeso molecular:344.37Aurora Kinases-IN-4
CAS:<p>Aurora Kinases-IN-4 (Compound 11c) is a covalent, ATP-competitive inhibitor of aurora kinase A with an IC50 value of 1.7 nM.</p>Fórmula:C26H28N8OPureza:98%Cor e Forma:SolidPeso molecular:468.55TC-A 2317 hydrochloride
CAS:<p>TC-A 2317 HCl inhibits Aurora A kinase (Ki 1.2 nM) over Aurora B (Ki 101 nM), displaying antitumor effects.</p>Fórmula:C19H29ClN6OPureza:98%Cor e Forma:SolidPeso molecular:392.93AAPK-25
CAS:AAPK-25, a dual Aurora/PLK inhibitor, disrupts mitosis, induces apoptosis, and has antitumor properties.Fórmula:C21H13Cl2N3O2SPureza:97.05%Cor e Forma:SolidPeso molecular:442.32Aurora kinase inhibitor-8
CAS:Aurora kinase inhibitor-8 is a highly selective inhibitor of Aurora kinase.Fórmula:C30H29N7O3Cor e Forma:SolidPeso molecular:535.6LY3295668
CAS:LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.Fórmula:C24H26ClF2N5O2Pureza:99.68%Cor e Forma:SolidPeso molecular:489.95CCT129202
CAS:CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively.Fórmula:C23H25ClN8OSPureza:98.14%Cor e Forma:SolidPeso molecular:497.02TY-011
CAS:<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Fórmula:C18H16ClN5Cor e Forma:SolidPeso molecular:337.81Glycyl H-1152 hydrochloride
CAS:Glycyl-H-1152 is a potent ROCK-II inhibitor (IC50=11.8 nM) with high selectivity over CaMKII, PKG, Aurora A, PKA, and PKC. Better than Y-27632 and HA-1077.Fórmula:C18H26Cl2N4O3SCor e Forma:SolidPeso molecular:449.39
